PET Center, Department of Radiological Sciences, Wake Forest University Medical Center, Winston Salem, NC 27157, USA.
Bioconjug Chem. 2009 Mar 18;20(3):583-90. doi: 10.1021/bc8005094.
In order to develop a PET radiopharmaceutical to image malignant melanoma, we synthesized N-(2-diethylaminoethyl)-4-[(18)F]fluorobenzamide ([(18)F]-DAFBA). In vitro studies show a high uptake of [(18)F]-DAFBA by the B16F1 melanoma cells. No significant binding was seen for DAFBA to the sigma-1 and sigma-2 receptors in vitro. The in vivo biodistribution studies performed in normal ICR mice showed a low uptake in the normal tissues followed by further elimination of radioactivity from these tissues with time. The biodistribution studies performed in C57 mice bearing the melanoma tumor xenograft showed a rapid uptake of radioactivity in the tumor that reached a plateau within 30 min postinjection. The F-18 uptake in the tumor was 7.00 +/- 2.76, 6.57 +/- 1.66, and 5.80 +/- 0.98%ID/g at 60, 120, and 180 min, respectively. A steady uptake of radioactivity in the tumor and low uptake in normal tissues resulted in high tumor to normal tissue ratios. For example, at 180 min postinjection, the tumor to tissue ratios were 14.90 +/- 6.47, 21.90 +/- 4.68, 32.91 +/- 6.11, 39.73 +/- 11.78, and 6.33 +/- 1.9, for the spleen, lungs, muscle, blood, and liver, respectively. The radioactivity rapidly cleared from the blood pool, and it decreased from 0.68 +/- 0.21%ID/g at 60 min to 0.13 +/- 0.03%ID/g at 180 min. The F-18 uptake in the bones at 60, 120, and 180 min was 0.91 +/- 0.27, 0.57 +/- 0.32, and 0.17 +/- 0.05%ID/g, respectively. This low uptake in the bones reflects its in vivo resistance toward defluorination. A low residual activity in normal tissues and a high tumor uptake signifies the superior imaging potential of this compound. Because of these positive traits, [(18)F]-DAFBA could help delineate the tumor and its metastases when used for imaging applications. Further in vivo studies are underway to assess the potential of [(18)F]-DAFBA as a promising PET imaging probe.
为了开发一种用于成像恶性黑色素瘤的 PET 放射性药物,我们合成了 N-(2-二乙基氨基乙基)-4-[(18)F]氟苯甲酰胺([(18)F]-DAFBA)。体外研究表明,B16F1 黑色素瘤细胞对[(18)F]-DAFBA 有很高的摄取率。在体外,DAFBA 与 sigma-1 和 sigma-2 受体没有明显的结合。在正常 ICR 小鼠中进行的体内生物分布研究表明,正常组织的摄取率较低,随后随着时间的推移,这些组织中的放射性活性进一步消除。在携带黑色素瘤肿瘤异种移植物的 C57 小鼠中进行的生物分布研究表明,放射性物质在肿瘤中的摄取速度很快,在注射后 30 分钟内达到平台期。肿瘤中的 F-18 摄取率分别为 60、120 和 180 分钟时的 7.00 +/- 2.76、6.57 +/- 1.66 和 5.80 +/- 0.98%ID/g。肿瘤中放射性物质的稳定摄取和正常组织中的低摄取导致了高肿瘤与正常组织的比值。例如,在注射后 180 分钟时,肿瘤与组织的比值分别为 14.90 +/- 6.47、21.90 +/- 4.68、32.91 +/- 6.11、39.73 +/- 11.78 和 6.33 +/- 1.9,分别为脾脏、肺、肌肉、血液和肝脏。放射性物质从血池迅速清除,从 60 分钟时的 0.68 +/- 0.21%ID/g 降至 180 分钟时的 0.13 +/- 0.03%ID/g。60、120 和 180 分钟时骨骼中的 F-18 摄取率分别为 0.91 +/- 0.27、0.57 +/- 0.32 和 0.17 +/- 0.05%ID/g。骨骼中的这种低摄取反映了其体内对脱氟的抵抗力。正常组织中的残留活性低,肿瘤摄取率高,表明该化合物具有优异的成像潜力。由于这些积极的特征,[(18)F]-DAFBA 可用于成像应用时有助于描绘肿瘤及其转移灶。正在进行进一步的体内研究,以评估 [(18)F]-DAFBA 作为一种有前途的 PET 成像探针的潜力。